Lyka Labs is an Indian pharmaceutical maker that has transformed from a small contract manufacturer into an innovation-led formulator under the wing of Ipca Laboratories - a larger industry player that took joint management control in 2022. The company was founded in 1976 in Ankleshwar, Gujarat, and spent decades as a job-work manufacturer before a series of restructurings, a debt clean-up, and the Ipca partnership gave it the balance-sheet strength to bet on proprietary R&D. The recurring approach is to take a difficult-to-make dosage form - a freeze-dried injectable, a patent-protected topical gel - master it in-house, and then let larger marketing partners carry it to patients while Lyka earns from the manufacturing and the molecule. # Business segments A single pharmaceutical engine, organised around two manufacturing specialisations and a growing animal-health sideline - all fed by an in-house R&D pipeline that turns novel formulations into branded, patent-protected products. ## 1. Sterile injectables and lyophilisation: the manufacturing backbone **The company runs a freeze-drying plant that makes injectable drugs in powder, liquid and lyophilised (freeze-dried) form - a high-barrier format that fewer rivals can handle reliably.** - **Built around lyophilisation** - lyophilisation (freeze-drying a drug into a stable powder that is reconstituted before injection) is the company’s signature capability, applied to both finished formulations and bulk sterile APIs, and housed in a dedicated plant at its Ankleshwar factory. - **Capacity is being stretched for regulated markets** - an expansion project at the lyophilisation plant is expected to lift capacity by roughly 50%, a move explicitly aimed at opening doors to tightly regulated markets such as Europe and the UK. - **Exports run on tenders, so they are lumpy** - international sales are driven by government tenders, and in FY24 those tenders underperformed because country budgets were exhausted and some markets faced currency turmoil, showing how the export order book depends on public-sector buying cycles. ## 2. Topical formulations and novel drug delivery: the proprietary pipeline **The company has moved beyond plain-vanilla creams into patent-protected gels and ointments that treat specific, hard-to-address conditions - and it licenses them to large marketing partners.** - **A patent that runs to 2043** - the standout asset is Pregabalin Gel 8% w/w, a novel topical gel for diabetic neuropathic pain that received an Indian patent and CDSCO approval in October 2024 after Phase III trials, and was launched in December 2024. - **Sold by others, made by Lyka** - the Pregabalin gel is marketed by Torrent Pharmaceuticals, Intas Pharmaceuticals and Zuventus Healthcare under a product-to-product licence, meaning Lyka captures the manufacturing and royalty economics while the marketing partners carry the selling cost. - **A string of dermatology firsts** - the R&D centre has also commercialised a Tofacitinib ointment for atopic dermatitis (approved November 2023), topical corticosteroid creams and lotions, and sunscreen gels in 30 SPF and 50 SPF, building a portfolio of clinically trialled derma products. - **Cosmeceuticals for export and private label** - the R&D pipeline extends into cosmeceuticals such as probiotic foaming face wash, skin-lightening gels and volumising shampoo, developed for the export market and for other companies’ brands on a principal-to-principal basis. ## 3. Animal healthcare: a small, acquired bet on veterinary brands **The company bought an established animal-health business in 2023 for a modest sum to gain a ready-made brand and distribution foothold in veterinary medicine.** - **Bought, not built from scratch** - the animal healthcare business was acquired from Agilis Healthcare Private Limited as a going concern for ₹3.25 crore in a slump sale effective January 2023, bringing with it assets, obligations and the brand trademark. - **First full year only just completed** - FY24 was the first full year of operations for the animal-health unit, so the business is still in its foundation stage, with the company focused on expanding its geographical reach and building a branded veterinary franchise both in India and abroad. # R&D engine **A government-recognised Mumbai lab turns out the formulations that the rest of the business runs on - and its work on novel drug delivery is what separates Lyka from a generic job-work shop.** - **Recognised by the science ministry** - the in-house R&D centre is approved by the Department of Scientific & Industrial Research, Government of India, and is staffed by technically qualified industry professionals. - **Develops across the full topical and injectable range** - the lab works on lyophilised injections, liquid injections, dry powder injections, and topical preparations including ointments, creams, lotions and gels, plus sustained-release tablets and cosmeceuticals. - **Clinical-trial tie-ups de-risk development** - the company has partnerships with medical institutions to carry out clinical trials, dermal toxicity studies, skin irritation and sensitivity tests, and comedogenicity studies, which helps it generate the data needed for regulatory approvals. - **Future pipeline is dermatology-heavy** - planned therapeutic segments include pain management, neuropathic pain, atopic dermatitis, acne, anti-ageing, fungal infections, skin lightening, moisturising and psoriasis, signalling a deliberate concentration in topical dermatology. # Group structure and partners **The company sits inside the Ipca Laboratories orbit, with two subsidiaries - one of which is being merged into the parent - and a web of related-party manufacturing relationships that provide both revenue and strategic cover.** - **Ipca is the anchor shareholder and joint controller** - Ipca Laboratories acquired a 27.76% stake through a public offer in FY22 and entered a joint management control agreement with the promoters; it has since converted warrants into equity and is now part of the promoter group, with related-party transactions in goods, contract manufacturing and loans capped at ₹50 crore. - **Two subsidiaries, one soon to disappear** - Lyka BDR International Limited (65.22% owned) distributes finished formulations in rest-of-world markets, while Lyka Exports Limited (72.80% owned) is being amalgamated into Lyka Labs itself, with the scheme becoming effective on 8 April 2026 and an appointed date of 1 April 2022. - **Other related-party manufacturing ties** - the company also transacts with Makers Laboratories Limited and Lyka Generics Limited for sale and purchase of materials, goods and contract manufacturing services, giving it additional production and commercial flexibility. - **An ESOP scheme aligns the team** - the Lyka ESOS 2025 permits granting up to 7,00,000 options (not more than 2% of paid-up equity) to eligible employees and key managerial personnel, with vesting over one to five years and an exercise price that can be discounted by up to 75% to the market price.